Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity.
about
Clinical Pharmacology and Cardiovascular Safety of NaproxenProstanoid receptor EP2 as a therapeutic targetInflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes.Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.Cyclooxygenase (COX) Inhibitors and the Newborn Kidney.Risk of stroke associated with nonsteroidal anti-inflammatory drugsEvolution to low-dose NSAID therapy.Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects.Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse - a population-based study of 16,253 incident patients with schizophrenia.Anti-Gouty Arthritis and Antihyperuricemia Effects of Sunflower (Helianthus annuus) Head Extract in Gouty and Hyperuricemia Animal Models.Mechanisms, Cofactors, and Augmenting Factors Involved in Anaphylaxis.Ruthenium(II)-catalyzed C-H activation with isocyanates: a versatile route to phthalimides.COX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles.Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk.Investigation of flurbiprofen genotoxicity and cytotoxicity in rat bone marrow cells.Nonsteroidal anti-inflammatory drugs enhance IgE-mediated activation of human basophils in patients with food anaphylaxis dependent on and independent of nonsteroidal anti-inflammatory drugs.
P2860
Q30360728-B7F7DA64-A045-4CF6-A7DD-1D2E3CF31BA6Q33711678-AE614695-7050-45D6-9DF6-BDA7FB658E62Q36023793-4FA30F83-503D-4739-AB6D-974414526961Q36444733-D71E9AC7-00A8-4DB1-990A-2AAF2019DF01Q36461735-1676C0BC-D805-4D02-9B56-21EBE431CF86Q37277333-9DE7921D-7D02-4E28-ACAA-D18FDD6BC133Q37464386-4BFEAB94-A931-4712-9EEC-A66506218420Q38776103-4A7F9CB8-3696-4B91-BC06-1A709C5C2C0FQ38836879-6F6A47D7-C280-407F-A282-3533F150FD86Q40847189-2B7ED3EB-0CF5-457E-80D7-89E8B81B7530Q41448685-E0461971-4018-4D3C-9867-D468AF4D2749Q42030753-EAFD1C80-A9ED-4380-9234-020B15F76DBCQ46841614-F95D269C-14CB-43C9-87F1-24735B8722BEQ48004224-3B268703-17A9-42DD-AFE2-DBE4A95D25ECQ52743780-C2759169-6860-4374-8A8B-FB5C06192B68Q54188765-E3AC8AED-64C3-493B-96DB-3F13C4D7CFFFQ54645888-36944D0C-CC55-4003-8100-71E4B74A475F
P2860
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Defining the COX inhibitor sel ...... ns for understanding toxicity.
@en
Defining the COX inhibitor sel ...... ns for understanding toxicity.
@nl
type
label
Defining the COX inhibitor sel ...... ns for understanding toxicity.
@en
Defining the COX inhibitor sel ...... ns for understanding toxicity.
@nl
prefLabel
Defining the COX inhibitor sel ...... ns for understanding toxicity.
@en
Defining the COX inhibitor sel ...... ns for understanding toxicity.
@nl
P2860
P356
P1476
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity
@en
P2093
John O Miners
Kathleen M Knights
P2860
P304
P356
10.1586/ECP.10.120
P407
P577
2010-11-01T00:00:00Z